TWI345978B - Combination therapy comprising glucose reabsorption inhibitors and retinoid x receptor modulators - Google Patents

Combination therapy comprising glucose reabsorption inhibitors and retinoid x receptor modulators

Info

Publication number
TWI345978B
TWI345978B TW091106917A TW91106917A TWI345978B TW I345978 B TWI345978 B TW I345978B TW 091106917 A TW091106917 A TW 091106917A TW 91106917 A TW91106917 A TW 91106917A TW I345978 B TWI345978 B TW I345978B
Authority
TW
Taiwan
Prior art keywords
combination therapy
retinoid
receptor modulators
glucose reabsorption
reabsorption inhibitors
Prior art date
Application number
TW091106917A
Other languages
English (en)
Chinese (zh)
Inventor
C Bussolari Jacqueling
Chen Xiaoli
C Johnson Bruce
Demarest Keith
N M Ross Hamish
Severino Rafael
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23077475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI345978(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of TWI345978B publication Critical patent/TWI345978B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Laminated Bodies (AREA)
TW091106917A 2001-04-04 2002-04-04 Combination therapy comprising glucose reabsorption inhibitors and retinoid x receptor modulators TWI345978B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28147901P 2001-04-04 2001-04-04
US10/115,725 US6838442B2 (en) 2001-04-04 2002-04-03 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators

Publications (1)

Publication Number Publication Date
TWI345978B true TWI345978B (en) 2011-08-01

Family

ID=23077475

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091106917A TWI345978B (en) 2001-04-04 2002-04-04 Combination therapy comprising glucose reabsorption inhibitors and retinoid x receptor modulators

Country Status (11)

Country Link
US (3) US6838442B2 (https=)
EP (1) EP1392326B1 (https=)
JP (1) JP4590158B2 (https=)
CN (1) CN100384430C (https=)
AT (1) ATE442148T1 (https=)
CA (1) CA2443325C (https=)
DE (1) DE60233655D1 (https=)
ES (1) ES2331561T3 (https=)
MY (1) MY148432A (https=)
TW (1) TWI345978B (https=)
WO (1) WO2002080935A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
IL157740A0 (en) 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
US7265139B2 (en) 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
NZ519403A (en) * 2001-06-21 2005-03-24 Pfizer Prod Inc Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
KR20060105431A (ko) * 2003-06-27 2006-10-11 닥터 레디스 리서치 파운데이션 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물
CN1319956C (zh) * 2003-09-12 2007-06-06 深圳市海粤门生物科技开发有限公司 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用
KR20070011379A (ko) 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2010141690A2 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Indane analogs and use as pharmaceutical agents and process of making
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA3114497A1 (en) 2013-01-18 2014-07-24 Cornell University Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
EP4727530A2 (en) * 2023-06-14 2026-04-22 President and Fellows of Harvard College Ion channel binders and uses thereof
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US651003A (en) * 1899-10-12 1900-06-05 Solomon W Bates Bicycle-pump.
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
JP2906978B2 (ja) * 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
ATE259227T1 (de) * 1995-09-18 2004-02-15 Ligand Pharm Inc Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
US5732199A (en) * 1996-09-25 1998-03-24 Behavior Tech Computer Corporation Control method and device of scanner with built-in plug-and-play printer port
AU719726B2 (en) * 1996-12-26 2000-05-18 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
AU8799998A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
NZ517993A (en) * 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
TW558554B (en) * 1999-10-29 2003-10-21 Takeda Chemical Industries Ltd Crystals of oxyiminoalkanoic acid derivative
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
MXPA03003870A (es) * 2000-10-30 2004-08-12 Johnson & Johnson Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
PL209375B1 (pl) * 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Also Published As

Publication number Publication date
MY148432A (en) 2013-04-30
US8183213B2 (en) 2012-05-22
US20090075864A1 (en) 2009-03-19
DE60233655D1 (de) 2009-10-22
CA2443325A1 (en) 2002-10-17
CN100384430C (zh) 2008-04-30
US20030055091A1 (en) 2003-03-20
US20030195235A1 (en) 2003-10-16
EP1392326A1 (en) 2004-03-03
WO2002080935A1 (en) 2002-10-17
CN1511038A (zh) 2004-07-07
US6838442B2 (en) 2005-01-04
ATE442148T1 (de) 2009-09-15
CA2443325C (en) 2011-06-14
ES2331561T3 (es) 2010-01-08
JP2004529914A (ja) 2004-09-30
JP4590158B2 (ja) 2010-12-01
EP1392326B1 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
TWI345978B (en) Combination therapy comprising glucose reabsorption inhibitors and retinoid x receptor modulators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
PT1333887E (pt) Metodo de tratamento de desordens musculares
MY142777A (en) Substituted indole-o-glucosides
MY151032A (en) Treatment of tnf? related disorders
UA87991C2 (en) Substituted indole-o-glucosides
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
YU38801A (sh) Azabicikloalkani kao modulatori ccr5
AU2001231763A1 (en) Dosing regimen
AU2002334579A1 (en) Medical device containing light-protected therapeutic agent
AU2003300791A1 (en) Combination therapy for the treatment of pain
AUPR839001A0 (en) Dosage form, device and methods of treatment
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
AU2003234425A1 (en) Methods for therapeutic treatment of carpal tunnel syndrome
AU1962801A (en) Device for treatment of spider veins
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
AU2002304883A1 (en) Device for the treatment of tumours
IL139144A0 (en) Mycobacterial inhibitors
AU2002327440A1 (en) Treatment of type i diabetes
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
AU2002235202A1 (en) Treatment of bone disorders by modulation of fgfr3
WO2003070177A3 (en) Use of melatonin analogues for induction of general anesthesia

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent